# Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

> **NCT00057356** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 170 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** conivaptan
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00057356
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2014-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057356, "Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00057356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*